Safe anticoagulation with danaparoid in pregnancy and lactation.
Schindewolf
Marc
M
Division of Vascular Medicine, I. Medical Department, Centre of Internal Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. marc_schindewolf@kgu.de
Mosch
Gerlinde
G
Bauersachs
Rupert M
RM
Lindhoff-Last
Edelgard
E
D020016:Activated Protein C Resistance / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D005165:Factor V / Q000235:genetics; D005260:Female; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D007774:Lactation; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control; D012449:Safety; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D005165:Factor V; D006497:Heparan Sulfate; C095381:factor V Leiden; C035838:danaparoid